Approaches and challenges in SARS-CoV-2 vaccine development
The explosive spread of SARS-CoV-2 suggests that a vaccine will be required to end this
global pandemic. Progress in SARS-CoV-2 vaccine development to date has been faster …
global pandemic. Progress in SARS-CoV-2 vaccine development to date has been faster …
[HTML][HTML] Research and development of universal influenza vaccines
L Du, Y Zhou, S Jiang - Microbes and infection, 2010 - Elsevier
The continuous threat of influenza pandemics determines the urgency and necessity to
develop safe and effective vaccines against divergent influenza viruses. This review …
develop safe and effective vaccines against divergent influenza viruses. This review …
[HTML][HTML] ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice
NK Alharbi, E Padron-Regalado, CP Thompson… - Vaccine, 2017 - Elsevier
Abstract The Middle East respiratory syndrome coronavirus (MERS-CoV) has infected more
than 1900 humans, since 2012. The syndrome ranges from asymptomatic and mild cases to …
than 1900 humans, since 2012. The syndrome ranges from asymptomatic and mild cases to …
A novel vaccine against Crimean-Congo Haemorrhagic Fever protects 100% of animals against lethal challenge in a mouse model
KR Buttigieg, SD Dowall, S Findlay-Wilson… - PloS one, 2014 - journals.plos.org
Crimean-Congo Haemorrhagic Fever (CCHF) is a severe tick-borne disease, endemic in
many countries in Africa, the Middle East, Eastern Europe and Asia. Between 15–70% of …
many countries in Africa, the Middle East, Eastern Europe and Asia. Between 15–70% of …
A Crimean-Congo hemorrhagic fever (CCHF) viral vaccine expressing nucleoprotein is immunogenic but fails to confer protection against lethal disease
SD Dowall, KR Buttigieg… - Human vaccines & …, 2016 - Taylor & Francis
Crimean-Congo Hemorrhagic Fever (CCHF) is a severe tick-borne disease, endemic in
many countries in Africa, the Middle East, Eastern Europe and Asia. Between 15–70% of …
many countries in Africa, the Middle East, Eastern Europe and Asia. Between 15–70% of …
Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors
C López-Camacho, P Abbink, RA Larocca… - Nature …, 2018 - nature.com
Zika virus (ZIKV) emerged on a global scale and no licensed vaccine ensures long-lasting
anti-ZIKV immunity. Here we report the design and comparative evaluation of four replication …
anti-ZIKV immunity. Here we report the design and comparative evaluation of four replication …
DNA vaccination induced protective immunity against SARS CoV-2 infection in hamsterss
KM Chai, TT Tzeng, KY Shen, HC Liao… - PLoS Neglected …, 2021 - journals.plos.org
The development of efficient vaccines against COVID-19 is an emergent need for global
public health. The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS …
public health. The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS …
OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple influenza A subtypes
J Del Campo, A Pizzorno, S Djebali, J Bouley, M Haller… - NPJ vaccines, 2019 - nature.com
Inactivated influenza vaccines (IIVs) lack broad efficacy. Cellular immunity to a conserved
internal antigen, the nucleoprotein (NP), has been correlated to protection against pandemic …
internal antigen, the nucleoprotein (NP), has been correlated to protection against pandemic …
Comparative assessment of vaccine vectors encoding ten malaria antigens identifies two protective liver-stage candidates
The development of an efficacious Plasmodium falciparum malaria vaccine remains a top
priority for global health. Vaccination with irradiated sporozoites is able to provide complete …
priority for global health. Vaccination with irradiated sporozoites is able to provide complete …
Signal peptide exchange alters HIV-1 envelope antigenicity and immunogenicity
C Upadhyay, P Rao, MA Behzadi… - Frontiers in …, 2024 - frontiersin.org
Introduction HIV-1 envelope (Env) is the key target for antibodies (Abs) against the virus and
thus an important HIV-1 vaccine component. Env is synthesized from a gp160 precursor with …
thus an important HIV-1 vaccine component. Env is synthesized from a gp160 precursor with …